Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00634751
Recruitment Status : Completed
First Posted : March 13, 2008
Results First Posted : August 8, 2017
Last Update Posted : August 8, 2017
Sponsor:
Collaborators:
Bayer
Sanofi
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:
This study involves the use of oxaliplatin, capecitabine, and sorafenib which are all drugs approved by the Food and Drug Administration (FDA) for use in the treatment of different cancers. Their use in this exact combination is considered experimental for the treatment of pancreas and biliary tract; however the combination has been tested in a preliminary trial. We are also testing a survey designed. The purpose of this research study is to investigate the chemotherapy drug sorafenib in combination with oxaliplatin and capecitabine chemotherapies for the treatment of pancreas and biliary tract cancers.to help patients report their side effects from chemotherapy treatments.

Condition or disease Intervention/treatment Phase
Pancreatic Neoplasms Bile Duct Neoplasms Drug: Oxaliplatin Drug: Capecitabine Drug: Sorafenib Phase 1 Phase 2

Detailed Description:

Primary Objectives

  • To assess the overall safety of sorafenib when administered with "the 2DOC regimen" capecitabine and oxaliplatin in patients with advanced or metastatic pancreas or biliary tract cancers.
  • To define the dose limiting toxicity and maximally tolerated dose of this combination.
  • To assess the clinical response rate (stable, partial and complete responses) of the combination in patients with advanced or metastatic pancreas or biliary tract cancers.

Secondary Objectives

  • To define the time to progression and overall survival for patients treated with this regimen.
  • To evaluate the congruency of the Adverse Events Self-Report Survey in determining patient reported side effects of treatment

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II STudy of Oxaliplatin, Oral Capecitabine and Sorafenib in Patients With Advanced Pancreatic and Biliary Carcinoma"
Study Start Date : February 2008
Actual Primary Completion Date : July 2010
Actual Study Completion Date : July 2010


Arm Intervention/treatment
Experimental: Phase I: 200mg Sorafenib+2DOC

Cohort 1: 200mg Sorafenib+2DOC

Oxaliplatin + Oral Capecitabine + Sorafenib

Drug: Oxaliplatin
On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.

Drug: Capecitabine
Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.

Drug: Sorafenib

Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).

Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length

Sorafenib 200 mg BID Oral Daily Every 28 days

If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.

Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length

Sorafenib 400 mg BID Oral Daily Every 28 days


Experimental: Phase I: 400mg Sorafenib BID+2DOC

Cohort 2: 400mg Sorafenib+2DOC

Oxaliplatin + Oral Capecitabine + Sorafenib

Drug: Oxaliplatin
On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.

Drug: Capecitabine
Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.

Drug: Sorafenib

Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).

Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length

Sorafenib 200 mg BID Oral Daily Every 28 days

If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.

Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length

Sorafenib 400 mg BID Oral Daily Every 28 days


Experimental: Phase II: Pancreatic Cancer
Oxaliplatin + Oral Capecitabine + Sorafeni
Drug: Oxaliplatin
On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.

Drug: Capecitabine
Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.

Drug: Sorafenib

Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).

Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length

Sorafenib 200 mg BID Oral Daily Every 28 days

If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.

Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length

Sorafenib 400 mg BID Oral Daily Every 28 days


Experimental: Phase II: Biliary Tract Cancer
Oxaliplatin + Oral Capecitabine + Sorafeni
Drug: Oxaliplatin
On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.

Drug: Capecitabine
Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.

Drug: Sorafenib

Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).

Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length

Sorafenib 200 mg BID Oral Daily Every 28 days

If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.

Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length

Sorafenib 400 mg BID Oral Daily Every 28 days





Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: Up to 18 months ]
    Response rate of participant to treatment


Secondary Outcome Measures :
  1. Progression-free Survival (PFS) [ Time Frame: Up to 18 months ]
    Time to progression, defined as number of days from day of first study drug administration to the day the patient experiences an event of disease progression or death; summarized using point estimates of the median time to progression and associated 95% confidence intervals for each stratum separately.

  2. Overall Survival [ Time Frame: Up to 18 months ]
    Overall survival, defined as number of days from the day of first study drug administration to the day the patient dies, summarized using point estimates of the median time to progression, and associated 95% confidence intervals



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed locally advanced inoperable or metastatic adenocarcinoma of the pancreas or biliary tract who have not previously received more than one systemic treatment for their disease.
  • Age at least 18 years old
  • ECOG performance status 0-2.
  • Patients must have adequate organ and marrow function as defined below:
  • WBC at least 3,000
  • ANC at least 1,500
  • PLT at least 100,000
  • total bilirubin must be less than 2.5 x institutional upper limit of norm
  • AST(SGOT)/ALT(SGPT) must be less than 5 X institutional upper limit of normal
  • creatinine clearance must be greater than 50 mL/min as calculated by the Cockroft-Gault formula
  • Patients with ≤ grade 2 (CTC 3.0) neuropathy.
  • At least one measurable lesion as defined by RECIST criteria
  • The effects of oxaliplatin, capecitabine and sorafenib on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because DNA alkylating agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Because the risk of toxicity in nursing infants secondary to oxaliplatin treatment of the mother is unknown but may be harmful, breastfeeding should be discontinued if the mother is treated with oxaliplatin.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • No concomitant radiation therapy, or other systemic cancer therapies.
  • Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other toxicities.
  • History of allergy to platinum compounds, capecitabine, sorafenib or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy.
  • Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, thrombolic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months, symptomatic congestive heart failure, unstable angina pectoris within 3 months prior to entry study, myocardial infarction within 6 months prior to study entry, ongoing cardiac arrhythmia (excluding atrial fibrillation), uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 90 mmHg, despite optimal medical management), pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug, or any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug, serious non-healing wound, ulcer, or bone fracture, evidence or history of bleeding diathesis or coagulopathy.
  • Pregnant or nursing women are excluded from this study because oxaliplatin, capecitabine and sorafenib is a DNA alkylating agent with the potential for teratogenic or abortifacient effects. Female patients of reproductive potential must have a negative urine or serum pregnancy test within two weeks prior to enrolling.
  • Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.
  • Because of drug interactions with sorafenib, use of St. John's Wort or rifampin (rifampicin) is contraindicated. Patients may discontinue the use of these drugs to become eligible for the study
  • Any condition that impairs patient's ability to swallow whole pills.
  • HIV-positive patients receiving anti-retroviral therapy (HAART) are excluded from the study because of possible pharmacokinetic interactions.
  • Second malignancy within the past 3 years (excluding nonmelanoma skin cancer and in situ cancers) that has not been treated with curative intent and is not currently without evidence of disease,
  • Patients with known gastrointestinal malabsorption syndromes are excluded as this concurrent illness will affect absorption of the oral medications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00634751


Locations
Layout table for location information
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
Bayer
Sanofi
Investigators
Layout table for investigator information
Principal Investigator: Noelle K LoConte, M.D. University of Wisconsin, Madison

Layout table for additonal information
Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT00634751     History of Changes
Other Study ID Numbers: 2007-0248
CO07204 ( Other Identifier: University of Wisconsin Carbone Cancer Center )
First Posted: March 13, 2008    Key Record Dates
Results First Posted: August 8, 2017
Last Update Posted: August 8, 2017
Last Verified: July 2017
Keywords provided by University of Wisconsin, Madison:
advanced pancreatic and biliary tract carcinomas
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Pancreatic Neoplasms
Bile Duct Neoplasms
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Biliary Tract Neoplasms
Bile Duct Diseases
Biliary Tract Diseases
Capecitabine
Oxaliplatin
Sorafenib
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors